244 related articles for article (PubMed ID: 32988266)
1. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
Ladha A; Mannis G; Muffly L
Leuk Lymphoma; 2021 Feb; 62(2):257-263. PubMed ID: 32988266
[TBL] [Abstract][Full Text] [Related]
2. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
[TBL] [Abstract][Full Text] [Related]
3. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].
Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K
Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216
[TBL] [Abstract][Full Text] [Related]
4. Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.
Mavrikou I; Chatzidimitriou D; Skoura L; Nikolousis E; Sakellari I; Gavriilaki E
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982695
[TBL] [Abstract][Full Text] [Related]
5. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
6. Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation.
Duncan C; St Martin A; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Pediatr Blood Cancer; 2021 Aug; 68(8):e29067. PubMed ID: 33871892
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Jabbour EJ; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1271-1280. PubMed ID: 30797942
[TBL] [Abstract][Full Text] [Related]
8. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
10. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes JE; de Lima M; Dombret H; Estey EH; Giralt SA; Montesinos P; Röllig C; Venditti A; Wang ES
J Hematol Oncol; 2020 Oct; 13(1):137. PubMed ID: 33059764
[TBL] [Abstract][Full Text] [Related]
11. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
[TBL] [Abstract][Full Text] [Related]
12. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
[TBL] [Abstract][Full Text] [Related]
13. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
[TBL] [Abstract][Full Text] [Related]
14. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
McDonald GB; Freston JW; Boyer JL; DeLeve LD
Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
[TBL] [Abstract][Full Text] [Related]
15. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin.
Sabatino D; Henneman A; Ahmad S; Jou E; Goldberg B
J Oncol Pharm Pract; 2023 Jun; 29(4):840-845. PubMed ID: 35293248
[TBL] [Abstract][Full Text] [Related]
17. A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
Izumi A; Tachibana T; Ando T; Tanaka M; Kanamori H; Nakajima H
Int J Hematol; 2022 Jan; 115(1):69-76. PubMed ID: 34490598
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
[TBL] [Abstract][Full Text] [Related]
19. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
Leopold LH; Berger MS; Feingold J
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
McKoy JM; Angelotta C; Bennett CL; Tallman MS; Wadleigh M; Evens AM; Kuzel TM; Trifilio SM; Raisch DW; Kell J; DeAngelo DJ; Giles FJ
Leuk Res; 2007 May; 31(5):599-604. PubMed ID: 16959316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
